tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2025-15-3s1-55-59tumors-1506Research ArticleСтатьиРак Фатерова сосочкаhttps://orcid.org/0000-0002-4822-5044ВладимироваЛ. Ю.

Владимирова Любовь Юрьевна

344037 Ростов-на-Дону, ул. 14‑я линия, 63

rnioi@list.ruhttps://orcid.org/0000-0002-2724-4000АлькинаА. К.

Алькина Анна Константиновна

344037 Ростов-на-Дону, ул. 14‑я линия, 63

https://orcid.org/0000-0003-0158-3757КалабановаЕ. А.

Калабанова Елена Александровна

344037 Ростов-на-Дону, ул. 14‑я линия, 63

ФГБУ «НМИЦ онкологии» Минздрава РоссииRussian Federation202530112025153s15559Copyright © Владимирова Л.Ю., Алькина А.К., Калабанова Е.А., 20252025Владимирова Л.Ю., Алькина А.К., Калабанова Е.А.Владимирова Л.Ю., Алькина А.К., Калабанова Е.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/1506

Ампулярная карцинома (АК) встречается крайне редко. Возникающие трудности при правильной постановке диагноза при АК связаны с анатомической сложностью и неоднородностью гистологических подтипов. Как правило, АК классифицируют на кишечный и панкреатобилиарный типы на основании морфологических и иммуногистохимических особенностей. В последние годы молекулярно-генетические исследования расширили представления о генетической структуре АК. Генные мутации служат прогностическими и предиктивными биомаркерами этой группы опухолей. В обзоре представлена информация о клинических симптомах, генетических особенностях, а также терапевтических стратегиях при АК.

ампулярный ракрак Фатерова сосочкагенетикахимиотерапия.ReferencesAhn D.H., Bekaii-Saab T. Ampullary cancer: an overview. Am Soc Clin Oncol Educ Book 2014;112–115. https://doi.org/10.14694/EdBook_AM.2014.34.112Ahn D.H., Bekaii-Saab T. Ampullary cancer: an overview. Am Soc Clin Oncol Educ Book 2014;112–115. https://doi.org/10.14694/EdBook_AM.2014.34.112Zheng-Pywell R., Reddy S. Ampullary Cancer. Surg Clin North Am. 2019;99(2):357–367. https://doi.org/10.1016/j.suc.2018.12.001Zheng-Pywell R., Reddy S. Ampullary Cancer. Surg Clin North Am. 2019;99(2):357–367. https://doi.org/10.1016/j.suc.2018.12.001Saha S.K., Zhu A.X., Fuchs C.S., Brooks G.A. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist 2016;21(5):594–599. https://doi.org/10.1634/theoncologist.2015-0446Saha S.K., Zhu A.X., Fuchs C.S., Brooks G.A. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist 2016;21(5):594–599. https://doi.org/10.1634/theoncologist.2015-0446Lemke J., Schafer D., Sander S., et al. Survival and prognostic factors in pancreatic and ampullary cancer. Anticancer Res 2014;34(6):3011–3020Lemke J., Schafer D., Sander S., et al. Survival and prognostic factors in pancreatic and ampullary cancer. Anticancer Res 2014;34(6):3011–3020Alessandrino F., Ivanovic A.M., Yee E.U., et al. MDCT and MRI of the ampulla of Vater. Part I: Technique optimization, normal anatomy, and epithelial neoplasms. Abdom. Imaging 2015;40:274–291. https://doi.org/10.1007/s00261-015-0528-3Alessandrino F., Ivanovic A.M., Yee E.U., et al. MDCT and MRI of the ampulla of Vater. Part I: Technique optimization, normal anatomy, and epithelial neoplasms. Abdom. Imaging 2015;40:274–291. https://doi.org/10.1007/s00261-015-0528-3Perone J.A., Riall T.S., Olino K. palliative care for pancreatic and periampullary cancer. Surg Clin North Am 2016;96(6):1415–1430. https://doi.org/10.1016/j.suc.2016.07.012Perone J.A., Riall T.S., Olino K. palliative care for pancreatic and periampullary cancer. Surg Clin North Am 2016;96(6):1415–1430. https://doi.org/10.1016/j.suc.2016.07.012Kimura W., Futakawa N., Yamagata S., et al. Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn J Cancer Res 1994;85(2):161–166. https://doi.org/10.1111/j.1349-7006.1994.tb02077.xKimura W., Futakawa N., Yamagata S., et al. Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn J Cancer Res 1994;85(2):161–166. https://doi.org/10.1111/j.1349-7006.1994.tb02077.xPerrone G., Santini D., Zagami M., et al. COX-2 expression of ampullary carcinoma: Correlation with different histotypes and clinicopathological parameters. Virchows Arch 2006;449(3):334–340. https://doi.org/10.1007/s00428-006-0255-9Perrone G., Santini D., Zagami M., et al. COX-2 expression of ampullary carcinoma: Correlation with different histotypes and clinicopathological parameters. Virchows Arch 2006;449(3):334–340. https://doi.org/10.1007/s00428-006-0255-9Liu X.-F., Tang K., Sun F.-B., et al. Partial resection of the pancreatic head and duodenum for management of carcinoma of the ampulla of vater: a case report. Anticancer Res 2016;36(3):1319–1324Liu X.-F., Tang K., Sun F.-B., et al. Partial resection of the pancreatic head and duodenum for management of carcinoma of the ampulla of vater: a case report. Anticancer Res 2016;36(3):1319–1324Panzeri F., Crippa S., Castelli P., et al. Management of ampullary neoplasms: A tailored approach between endoscopy and surgery. World J Gastroenterol 2015;21:7970–7987. https://doi.org/10.3748/wjg.v21.i26.7970Panzeri F., Crippa S., Castelli P., et al. Management of ampullary neoplasms: A tailored approach between endoscopy and surgery. World J Gastroenterol 2015;21:7970–7987. https://doi.org/10.3748/wjg.v21.i26.7970Chun Y.S., Pawlik T.M., Vauthey J.-N. 8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers. Ann Surg Oncol 2018;25:845–847. https://doi.org/10.1245/s10434-017-6025-xChun Y.S., Pawlik T.M., Vauthey J.-N. 8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers. Ann Surg Oncol 2018;25:845–847. https://doi.org/10.1245/s10434-017-6025-xKang S.H., Kim K.H., Kim T.N., et al. Therapeutic outcomes of endoscopic papillectomy for ampullary neoplasms: retrospective analysis of a multicenter study. BMC Gastroenterol 2017;17(1):69. https://doi.org/10.1186/s12876-017-0626-5Kang S.H., Kim K.H., Kim T.N., et al. Therapeutic outcomes of endoscopic papillectomy for ampullary neoplasms: retrospective analysis of a multicenter study. BMC Gastroenterol 2017;17(1):69. https://doi.org/10.1186/s12876-017-0626-5Kim H.N., Kim K.M., Shin J.U., et al. Prediction of carcinoma after resection in subjects with ampullary adenomas on endoscopic biopsy. J Clin Gastroenterol 2013;47(4):346–351. https://doi.org/10.1097/MCG.0b013e318272f2efKim H.N., Kim K.M., Shin J.U., et al. Prediction of carcinoma after resection in subjects with ampullary adenomas on endoscopic biopsy. J Clin Gastroenterol 2013;47(4):346–351. https://doi.org/10.1097/MCG.0b013e318272f2efGrobmyer S.R., Stasik C.N., Draganov P., et al. Contemporary results with ampullectomy for 29“benign” neoplasms of the ampulla. J Am Coll Surg 2008;206(3):466–471. https://doi.org/10.1016/j.jamcollsurg.2007.09.005Grobmyer S.R., Stasik C.N., Draganov P., et al. Contemporary results with ampullectomy for 29“benign” neoplasms of the ampulla. J Am Coll Surg 2008;206(3):466–471. https://doi.org/10.1016/j.jamcollsurg.2007.09.005Lee-Six H., Olafsson S., Ellis P., et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature 2019;574:532–537. https://doi.org/10.1038/s41586-019-1672-7Lee-Six H., Olafsson S., Ellis P., et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature 2019;574:532–537. https://doi.org/10.1038/s41586-019-1672-7Dinarvand P., Davaro E.P., Doan J.V., et al. Familial adenomatous polyposis syndrome: an update and review of extraintestinal manifestations. Arch Pathol Lab Med 2019;143:1382–1398. https://doi.org/10.5858/arpa.2018-0570-RADinarvand P., Davaro E.P., Doan J.V., et al. Familial adenomatous polyposis syndrome: an update and review of extraintestinal manifestations. Arch Pathol Lab Med 2019;143:1382–1398. https://doi.org/10.5858/arpa.2018-0570-RAKwon M.J., Kim J.W., Jung J.P., et al. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value. Hum Pathol 2016;50:90–100. https://doi.org/10.1016/j.humpath.2015.11.009Kwon M.J., Kim J.W., Jung J.P., et al. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value. Hum Pathol 2016;50:90–100. https://doi.org/10.1016/j.humpath.2015.11.009Yachida S., Wood L.D., Suzuki M., et al. Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma. Cancer Cell 2016;29(2):229–240. https://doi.org/10.1016/j.ccell.2015.12.012Yachida S., Wood L.D., Suzuki M., et al. Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma. Cancer Cell 2016;29(2):229–240. https://doi.org/10.1016/j.ccell.2015.12.012Gingras M.-C., Covington K.R., Chang D.K., et al. Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation. Cell Rep 2016;14:907–919. https://doi.org/10.1016/j.celrep.2015.12.005Gingras M.-C., Covington K.R., Chang D.K., et al. Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation. Cell Rep 2016;14:907–919. https://doi.org/10.1016/j.celrep.2015.12.005Kinugasa H., Kanzaki H., Tanaka T., et al. The impact of KRAS mutation in patients with sporadic nonampullary duodenal epithelial tumors. Clin Transl Gastroenterol 2021;12(11):e00424. https://doi.org/10.14309/ctg.0000000000000424Kinugasa H., Kanzaki H., Tanaka T., et al. The impact of KRAS mutation in patients with sporadic nonampullary duodenal epithelial tumors. Clin Transl Gastroenterol 2021;12(11):e00424. https://doi.org/10.14309/ctg.0000000000000424Mafficini A., Amato E., Cataldo I., et al. Ampulla of Vater carcinoma: Sequencing analysis identifies TP53 status as a novel independent prognostic factor and potentially actionable ERBB, PI3K, and WNT pathways gene mutations. Ann Surg 2018;267:149–156. https://doi.org/10.1097/SLA.0000000000001999Mafficini A., Amato E., Cataldo I., et al. Ampulla of Vater carcinoma: Sequencing analysis identifies TP53 status as a novel independent prognostic factor and potentially actionable ERBB, PI3K, and WNT pathways gene mutations. Ann Surg 2018;267:149–156. https://doi.org/10.1097/SLA.0000000000001999Wong W., Lowery M.A., Berger M.F., et al. Ampullary cancer: evaluation of somatic and germline genetic alterations and association with clinical outcomes. Cancer 2019;125(9):1441–1448. https://doi.org/10.1002/cncr.31951Wong W., Lowery M.A., Berger M.F., et al. Ampullary cancer: evaluation of somatic and germline genetic alterations and association with clinical outcomes. Cancer 2019;125(9):1441–1448. https://doi.org/10.1002/cncr.31951Kumari N., Singh R.K., Mishra S.K., et al. Identification of PI3K-AKT signaling as the dominant altered pathway in intestinal type ampullary cancers through whole-exome sequencing. J Pathol Transl Med 2021;55(3):192–201. https://doi.org/10.4132/jptm.2021.01.23Kumari N., Singh R.K., Mishra S.K., et al. Identification of PI3K-AKT signaling as the dominant altered pathway in intestinal type ampullary cancers through whole-exome sequencing. J Pathol Transl Med 2021;55(3):192–201. https://doi.org/10.4132/jptm.2021.01.23Harthimmer M.R., Stolborg U., Pfeiffer P., et al. Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas. J Clin Pathol 2019;72(11):762–770. https://doi.org/10.1136/jclinpath-2019-205912Harthimmer M.R., Stolborg U., Pfeiffer P., et al. Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas. J Clin Pathol 2019;72(11):762–770. https://doi.org/10.1136/jclinpath-2019-205912Yeh C.-C., Jeng Y.-M., Ho C.-M., et al. Survival after pancreaticoduodenectomy for ampullary cancer is not affected by age. World J Surg 2010;34:2945–2952. https://doi.org/10.1007/s00268-010-0759-yYeh C.-C., Jeng Y.-M., Ho C.-M., et al. Survival after pancreaticoduodenectomy for ampullary cancer is not affected by age. World J Surg 2010;34:2945–2952. https://doi.org/10.1007/s00268-010-0759-yNeoptolemos J.P., Moore M.J., Cox T.F., et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012;308(2):147–156. https://doi.org/10.1001/jama.2012.7352Neoptolemos J.P., Moore M.J., Cox T.F., et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012;308(2):147–156. https://doi.org/10.1001/jama.2012.7352Chiorean E.G., Chiaro M.D., Tempero M.A., et al. Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2023;21(7):753–782. https://doi.org/10.6004/jnccn.2023.0034Chiorean E.G., Chiaro M.D., Tempero M.A., et al. Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2023;21(7):753–782. https://doi.org/10.6004/jnccn.2023.0034Ледин Е.В., Лядов В.К., Мороз Е.А. и соавт. Рак тонкой кишки и ампулы Фатерова сосочка. Практические рекомендации RUSSCO, часть 1.1. Злокачественные опухоли 2024;14(3s2):323–341. https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-15Ледин Е.В., Лядов В.К., Мороз Е.А. и соавт. Рак тонкой кишки и ампулы Фатерова сосочка. Практические рекомендации RUSSCO, часть 1.1. Злокачественные опухоли 2024;14(3s2):323–341. https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-15Hammel P., Huguet F., van Laethem J.L., et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 2016;315(17):1844–1853. https://doi.org/10.1001/jama.2016.4324Hammel P., Huguet F., van Laethem J.L., et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 2016;315(17):1844–1853. https://doi.org/10.1001/jama.2016.4324Drilon A., Laetsch T.W., Kummar S., et al. Ef cacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378(8):731–739. https://doi.org/10.1056/NEJMoa1714448Drilon A., Laetsch T.W., Kummar S., et al. Ef cacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378(8):731–739. https://doi.org/10.1056/NEJMoa1714448Doebele R.C., Drilon A., Paz-Ares L., et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 2020;21(2):271–282. https://doi.org/10.1016/S1470-2045(19)30691-6Doebele R.C., Drilon A., Paz-Ares L., et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 2020;21(2):271–282. https://doi.org/10.1016/S1470-2045(19)30691-6Salama A.K., Li S., Macrae E.R., et al. Dabrafenib and trametinib in patients with tumors with BRAF(V600E) mutations: results of the NCI-MATCH trial Subprotocol H. J Clin Oncol 2020;38(33):3895–3904. https://doi.org/10.1200/JCO.20.00762Salama A.K., Li S., Macrae E.R., et al. Dabrafenib and trametinib in patients with tumors with BRAF(V600E) mutations: results of the NCI-MATCH trial Subprotocol H. J Clin Oncol 2020;38(33):3895–3904. https://doi.org/10.1200/JCO.20.00762Subbiah V., Lassen U., Elez E., et al. Dabrafenib plus trametinib in patients with BRAFV600E mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020;21(9):1234–1243. https://doi.org/10.1016/S1470-2045(20)30321-1.Subbiah V., Lassen U., Elez E., et al. Dabrafenib plus trametinib in patients with BRAFV600E mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020;21(9):1234–1243. https://doi.org/10.1016/S1470-2045(20)30321-1.

The authors declare that there are no conflicts of interest present.